Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development

William W. Lockwood, Ian M. Wilson, Bradley P. Coe, Raj Chari, Larissa A. Pikor, Kelsie L. Thu, Luisa M. Solis, Maria I. Nunez, Carmen Behrens, John Yee, John English, Nevin Murray, Ming Sound Tsao, John D. Minna, Adi F. Gazdar, Ignacio I. Wistuba, Calum E. MacAulay, Stephen Lam, Wan L. Lam

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

For therapeutic purposes, non-small cell lung cancer (NSCLC) has traditionally been regarded as a single disease. However, recent evidence suggest that the two major subtypes of NSCLC, adenocarcinoma (AC) and squamous cell carcinoma (SqCC) respond differently to both molecular targeted and new generation chemotherapies. Therefore, identifying the molecular differences between these tumor types may impact novel treatment strategy. We performed the first large-scale analysis of 261 primary NSCLC tumors (169 AC and 92 SqCC), integrating genome-wide DNA copy number, methylation and gene expression profiles to identify subtype-specific molecular alterations relevant to new agent design and choice of therapy. Comparison of AC and SqCC genomic and epigenomic landscapes revealed 778 altered genes with corresponding expression changes that are selected during tumor development in a subtype-specific manner. Analysis of >200 additional NSCLCs confirmed that these genes are responsible for driving the differential development and resulting phenotypes of AC and SqCC. Importantly, we identified key oncogenic pathways disrupted in each subtype that likely serve as the basis for their differential tumor biology and clinical outcomes. Downregulation of HNF4α target genes was the most common pathway specific to AC, while SqCC demonstrated disruption of numerous histone modifying enzymes as well as the transcription factor E2F1. In silico screening of candidate therapeutic compounds using subtype-specific pathway components identified HDAC and PI3K inhibitors as potential treatments tailored to lung SqCC. Together, our findings suggest that AC and SqCC develop through distinct pathogenetic pathways that have significant implication in our approach to the clinical management of NSCLC.

Original languageEnglish (US)
Article numbere37775
JournalPLoS One
Volume7
Issue number5
DOIs
StatePublished - May 21 2012

Fingerprint

squamous cell carcinoma
lung neoplasms
Epigenomics
epigenetics
adenocarcinoma
Tumors
Squamous Cell Carcinoma
Lung Neoplasms
genomics
neoplasms
Adenocarcinoma
Non-Small Cell Lung Carcinoma
Genes
Neoplasms
therapeutics
E2F1 Transcription Factor
cells
Therapeutics
Histone Deacetylase Inhibitors
Methylation

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. / Lockwood, William W.; Wilson, Ian M.; Coe, Bradley P.; Chari, Raj; Pikor, Larissa A.; Thu, Kelsie L.; Solis, Luisa M.; Nunez, Maria I.; Behrens, Carmen; Yee, John; English, John; Murray, Nevin; Tsao, Ming Sound; Minna, John D.; Gazdar, Adi F.; Wistuba, Ignacio I.; MacAulay, Calum E.; Lam, Stephen; Lam, Wan L.

In: PLoS One, Vol. 7, No. 5, e37775, 21.05.2012.

Research output: Contribution to journalArticle

Lockwood, WW, Wilson, IM, Coe, BP, Chari, R, Pikor, LA, Thu, KL, Solis, LM, Nunez, MI, Behrens, C, Yee, J, English, J, Murray, N, Tsao, MS, Minna, JD, Gazdar, AF, Wistuba, II, MacAulay, CE, Lam, S & Lam, WL 2012, 'Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development', PLoS One, vol. 7, no. 5, e37775. https://doi.org/10.1371/journal.pone.0037775
Lockwood, William W. ; Wilson, Ian M. ; Coe, Bradley P. ; Chari, Raj ; Pikor, Larissa A. ; Thu, Kelsie L. ; Solis, Luisa M. ; Nunez, Maria I. ; Behrens, Carmen ; Yee, John ; English, John ; Murray, Nevin ; Tsao, Ming Sound ; Minna, John D. ; Gazdar, Adi F. ; Wistuba, Ignacio I. ; MacAulay, Calum E. ; Lam, Stephen ; Lam, Wan L. / Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. In: PLoS One. 2012 ; Vol. 7, No. 5.
@article{1614a628114e429284ce25350c6e0dda,
title = "Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development",
abstract = "For therapeutic purposes, non-small cell lung cancer (NSCLC) has traditionally been regarded as a single disease. However, recent evidence suggest that the two major subtypes of NSCLC, adenocarcinoma (AC) and squamous cell carcinoma (SqCC) respond differently to both molecular targeted and new generation chemotherapies. Therefore, identifying the molecular differences between these tumor types may impact novel treatment strategy. We performed the first large-scale analysis of 261 primary NSCLC tumors (169 AC and 92 SqCC), integrating genome-wide DNA copy number, methylation and gene expression profiles to identify subtype-specific molecular alterations relevant to new agent design and choice of therapy. Comparison of AC and SqCC genomic and epigenomic landscapes revealed 778 altered genes with corresponding expression changes that are selected during tumor development in a subtype-specific manner. Analysis of >200 additional NSCLCs confirmed that these genes are responsible for driving the differential development and resulting phenotypes of AC and SqCC. Importantly, we identified key oncogenic pathways disrupted in each subtype that likely serve as the basis for their differential tumor biology and clinical outcomes. Downregulation of HNF4α target genes was the most common pathway specific to AC, while SqCC demonstrated disruption of numerous histone modifying enzymes as well as the transcription factor E2F1. In silico screening of candidate therapeutic compounds using subtype-specific pathway components identified HDAC and PI3K inhibitors as potential treatments tailored to lung SqCC. Together, our findings suggest that AC and SqCC develop through distinct pathogenetic pathways that have significant implication in our approach to the clinical management of NSCLC.",
author = "Lockwood, {William W.} and Wilson, {Ian M.} and Coe, {Bradley P.} and Raj Chari and Pikor, {Larissa A.} and Thu, {Kelsie L.} and Solis, {Luisa M.} and Nunez, {Maria I.} and Carmen Behrens and John Yee and John English and Nevin Murray and Tsao, {Ming Sound} and Minna, {John D.} and Gazdar, {Adi F.} and Wistuba, {Ignacio I.} and MacAulay, {Calum E.} and Stephen Lam and Lam, {Wan L.}",
year = "2012",
month = "5",
day = "21",
doi = "10.1371/journal.pone.0037775",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development

AU - Lockwood, William W.

AU - Wilson, Ian M.

AU - Coe, Bradley P.

AU - Chari, Raj

AU - Pikor, Larissa A.

AU - Thu, Kelsie L.

AU - Solis, Luisa M.

AU - Nunez, Maria I.

AU - Behrens, Carmen

AU - Yee, John

AU - English, John

AU - Murray, Nevin

AU - Tsao, Ming Sound

AU - Minna, John D.

AU - Gazdar, Adi F.

AU - Wistuba, Ignacio I.

AU - MacAulay, Calum E.

AU - Lam, Stephen

AU - Lam, Wan L.

PY - 2012/5/21

Y1 - 2012/5/21

N2 - For therapeutic purposes, non-small cell lung cancer (NSCLC) has traditionally been regarded as a single disease. However, recent evidence suggest that the two major subtypes of NSCLC, adenocarcinoma (AC) and squamous cell carcinoma (SqCC) respond differently to both molecular targeted and new generation chemotherapies. Therefore, identifying the molecular differences between these tumor types may impact novel treatment strategy. We performed the first large-scale analysis of 261 primary NSCLC tumors (169 AC and 92 SqCC), integrating genome-wide DNA copy number, methylation and gene expression profiles to identify subtype-specific molecular alterations relevant to new agent design and choice of therapy. Comparison of AC and SqCC genomic and epigenomic landscapes revealed 778 altered genes with corresponding expression changes that are selected during tumor development in a subtype-specific manner. Analysis of >200 additional NSCLCs confirmed that these genes are responsible for driving the differential development and resulting phenotypes of AC and SqCC. Importantly, we identified key oncogenic pathways disrupted in each subtype that likely serve as the basis for their differential tumor biology and clinical outcomes. Downregulation of HNF4α target genes was the most common pathway specific to AC, while SqCC demonstrated disruption of numerous histone modifying enzymes as well as the transcription factor E2F1. In silico screening of candidate therapeutic compounds using subtype-specific pathway components identified HDAC and PI3K inhibitors as potential treatments tailored to lung SqCC. Together, our findings suggest that AC and SqCC develop through distinct pathogenetic pathways that have significant implication in our approach to the clinical management of NSCLC.

AB - For therapeutic purposes, non-small cell lung cancer (NSCLC) has traditionally been regarded as a single disease. However, recent evidence suggest that the two major subtypes of NSCLC, adenocarcinoma (AC) and squamous cell carcinoma (SqCC) respond differently to both molecular targeted and new generation chemotherapies. Therefore, identifying the molecular differences between these tumor types may impact novel treatment strategy. We performed the first large-scale analysis of 261 primary NSCLC tumors (169 AC and 92 SqCC), integrating genome-wide DNA copy number, methylation and gene expression profiles to identify subtype-specific molecular alterations relevant to new agent design and choice of therapy. Comparison of AC and SqCC genomic and epigenomic landscapes revealed 778 altered genes with corresponding expression changes that are selected during tumor development in a subtype-specific manner. Analysis of >200 additional NSCLCs confirmed that these genes are responsible for driving the differential development and resulting phenotypes of AC and SqCC. Importantly, we identified key oncogenic pathways disrupted in each subtype that likely serve as the basis for their differential tumor biology and clinical outcomes. Downregulation of HNF4α target genes was the most common pathway specific to AC, while SqCC demonstrated disruption of numerous histone modifying enzymes as well as the transcription factor E2F1. In silico screening of candidate therapeutic compounds using subtype-specific pathway components identified HDAC and PI3K inhibitors as potential treatments tailored to lung SqCC. Together, our findings suggest that AC and SqCC develop through distinct pathogenetic pathways that have significant implication in our approach to the clinical management of NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=84861324338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861324338&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0037775

DO - 10.1371/journal.pone.0037775

M3 - Article

C2 - 22629454

AN - SCOPUS:84861324338

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e37775

ER -